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Abstract
Background Recently published guidelines on the
medical management of renal stone disease did not
address relevant topics in the field of idiopathic calcium
nephrolithiasis, which are important also for clinical
research.
Design A steering committee identified 27 questions, which
were proposed to a faculty of 44 experts in nephrolithiasis
and allied fields. A systematic review of the literature was
conducted and 5216 potentially relevant articles were
selected; from these, 407 articles were deemed to provide
useful scientific information. The Faculty, divided into
working groups, analysed the relevant literature. Preliminary
statements developed by each group were exhaustively
discussed in plenary sessions and approved.
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Results Statements were developed to inform clinicians
on the identification of secondary forms of calcium
nephrolithiasis and systemic complications; on the defi-
nition of idiopathic calcium nephrolithiasis; on the use
of urinary tests of crystallization and of surgical obser-
vations during stone treatment in the management of
these patients; on the identification of patients warrant-
ing preventive measures; on the role of fluid and nutri-
tional measures and of drugs to prevent recurrent
episodes of stones; and finally, on the cooperation
between the urologist and nephrologist in the renal stone
patients.
Conclusions This document has addressed idiopathic cal-
cium nephrolithiasis from the perspective of a disease that
can associate with systemic disorders, emphasizing the
interplay needed between urologists and nephrologists. It is
complementary to the American Urological Association
and European Association of Urology guidelines. Future
areas for research are identified.
Keywords Nephrolithiasis  CKD  Bone disease  Diet 
Beverages  Renal tubular acidosis
Introduction
The present document is the result of a Consensus Con-
ference held in Rome on March 26–28, 2015 that con-
cluded the work of an International Faculty of experts in
the field of renal stones. The faculty was multidisciplinary,
representing nephrology, urology, nutrition, internal med-
icine, endocrinology, and laboratory medicine, which was
desirable in view of the multifaceted nature of
nephrolithiasis and in line with the scientific ‘tradition’ in
this field.
In 2014 and 2015, three clinical practice guidelines
addressing the medical management of nephrolithiasis
were published: the American Urological Association
(AUA) [1], American College of Physicians (ACP) [2], and
European Association of Urology (EAU) [3] guidelines.
These guidelines underlie the interest in this condition that
is increasing in prevalence, and is difficult to treat because
of its unpredictability, complexity and heterogeneity. Last
but not least, they also highlight the need for increased
knowledge regarding key pathogenic aspects and newer
treatment strategies.
Why another consensus statement on nephrolithiasis?
The answer is relatively easy, expressed as three goals:
1. To address questions that have not been addressed by
previous documents;
2. To address those questions with a more general
perspective for a disease that can be associated with
systemic disorders.
3. To emphasize primarily the interplay between urolo-
gists and nephrologists, but also with other medical
experts in the management of this disorder.
Of course, it is not all black and white, in the sense that
some of the questions, or some of the relevant systemic
disorders, were in part also addressed by other documents.
However, in general, this statement is complementary to
the other recent documents; in the areas of overlap, it
partially endorses the AUA and EAU guidelines with a few
modifications. This consensus statement was born in a
strong mixed uro-nephrological collaboration with an
accent on some typical renal medicine issues, i.e. chronic
kidney disease (CKD), metabolic bone disease (MBD), and
with an attempt to define the areas of cooperation.
Furthermore, different from other documents, some of
the questions discussed in this statement represent the
cutting edge of a relevant new understanding of the
disorder (i.e. question #14: Use of surgical observations
for diagnosis); and some are relevant not only from a
good clinical practice perspective, but also for future
research. For example, this statement addresses how to
define the clinical phenotype of the idiopathic calcium
nephrolithiasis (CN) patient, and the definition of clini-
cal activity of the CN, both useful in designing ran-
domized clinical trials (RCT), that are largely lacking in
this field of medicine.
This document addresses only the so-called idiopathic
CN; non-idiopathic calcium stones, uric acid, cystine and
struvite stones are addressed just for those aspects needed
to identify and manage the idiopathic CN.
Methods
A Steering Committee which was set up by a previous
conference (Nephrolithiasis: a systemic disorder, Rome,
March 21–23, 2013) discussed which questions should be
asked; these were selected because of clinical relevance,
and/or the insufficient consensus on them, and/or not
having been addressed by other documents, and/or to
address topics for the development of cooperation between
nephrologists and urologists. Twenty-seven questions
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were, in the end, proposed to a panel whose members were
selected according to their expertise in nephrolithiasis and
allied fields.
The task of the Steering Committee was to develop
recommendations based on the analysis of the literature
or on the consensus of the Faculty for best clinical
practice in the management of CN patients. The whole
Faculty, including the Steering Committee, comprised
44 members which were divided into working groups of
4–5 members each to analyse ahead of the conference
the relevant literature, and to carry out, whenever
necessary, on-line surveys among the community
involved in the treatment of renal stone patients,
including urologists and nephrologists and other spe-
cialists (clinical epidemiologists, nutritionists, bio-
chemists, etc.). Working groups addressed 2–4
questions each. All the work and preliminary statements
developed by each group were presented to the Faculty
in plenary sessions in Rome where they were exhaus-
tively discussed during 1.5 days, at the end of which
each working group met to revise their statements in
view of the plenary discussions and the results of other
working groups’ possibly interrelated results. The fol-
lowing day, the revised versions of all statements were
presented to the Faculty, discussed and approved. Fol-
lowing the conference, the consensus statement draft
prepared by members of a writing committee was sub-
mitted to all members of the Consensus Conference
Group for final revision.
Analytical procedure
The groups performed a systematic review of the liter-
ature to retrieve all randomized clinical trials (RCT) that
investigated topics relevant to their assigned questions.
Cohort and case–control studies in addition to RCTs
were also considered in the analysis due to the very
small number of RCT-based evidence available in the
literature.
Using appropriate search strategies, potentially relevant
titles and abstracts published up to June 2014 were
retrieved, from which 5216 potentially relevant articles
were selected; from these, 3855 records were excluded
based on title/abstract; 954 were excluded after screening
the abstract or reading the article. In the end, 407 articles
were deemed to provide useful scientific information.
The definition of the scientific ‘strength’ of each state-
ment was based on the AUA categorization (http://www.
auanet.org/education/guidelines/management-kidney-
stones.cfm).
Questions and consensus statements
Questions #1 and #2
Is the stone patient at risk of CKD?
Is it necessary to implement this information in the
evaluation of the renal stone former?
Although the effect size is modest, nephrolithiasis
should be viewed as a condition that may lead to CKD.
Thus, in patients with renal stones the evaluation of the
global risk (comorbidities) of developing CKD/end-
stage renal disease (ESRD) is mandatory. Those who
are female and overweight, or with frequent urinary
tract infections (UTI) or struvite stones, with urinary
malformations and urinary diversion, malabsorptive
bowel diseases, monogenic disorders and need of
repeated stone surgeries have a particularly high risk
of CKD/ESRD (Clinical principle).
In a registry cohort study, one or more stone episodes were
associated with an increased risk of ESRD [adjusted hazard
ratio (HR) 2.16, 1.79–2.62], new stage 3b-5 CKD (1.74,
1.61–1.88), and doubling of serum creatinine (1.94,
1.56–2.43). However, the absolute increase in the rate of
ESRD associated with stones was small (2.48 per million
person days in people with stones versus 0.52 in people
without) [4].The risk seems to be greater in women than in
men [4, 5]. In the Olmsted County cohort studies, those
stone formers who developed CKD or ESRD were more
likely to have a history of hydronephrosis, struvite stones,
recurrent UTI, acquired single kidney (15 vs. 3 %), neu-
rogenic bladder (12 vs. 1 %), and ileal conduit (9 vs. 0 %)
[6, 7]. Among the Third National Health and Nutrition
Examination Survey (NHANES III) participants, a history
of kidney stones in subjects with body mass index
(BMI) C 27 kg/m2 increased the probability of having an
estimated glomerular filtration rate (eGFR)\ 60 ml/min/
1.73 m2 compared to overweight non-stone formers [8].
Stone formers with cystinuria, uric acid or struvite stones,
renal tubular acidosis, or chronic bowel disorders fre-
quently manifest decreased GFR, and CKD/ESRD [9, 10].
Standard Roux-en-Y gastric bypass and malabsorptive
types of bariatric surgery are both associated with an
increased risk for stones and CKD [11]. In a multicenter
registry study on 5,745 patients undergoing percutaneous
nephrolithotomy (PCNL), the risk of CKD was associated
with the number of procedures for stone removal [12].
Lowquality studies donot permit a confident conclusionon
the relevance of kidney damage induced by urological stone
procedures and thedevelopment andprogressionofCKD.The
J Nephrol (2016) 29:715–734 717
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high-speed of technological advancements in urology does
not easily allow for comparison between study cohorts, even
when investigated over a short space of time. Although non-
invasive and mini-invasive urological procedures for stone
removal do damage the kidney to a certain extent, the differ-
entiation of the renal damage due to the urological procedure
versus the stone disease itself is a challenge.
Future research directions
• Studies to evaluate the risk of CKD according to
etiology and composition of renal stones.
• Registry studies on the effect of different urological
treatments of renal stones. This requires a minimum
standard for data acquisition (e.g. stone burden, stone
composition, concomitant obstruction, concomitant
infection, urological procedure(s), repeated procedures.
• Methods for the evaluation of the renal damage in stone
formers.
Questions #3 and #4
Is the calcium stone patient at risk of bone disease
and if so, how should that risk be addressed?
Is it necessary to implement this information in the
evaluation of the renal stone former?
Stone patients with hypercalciuria should be evaluated
for the global risk of osteoporosis. Those who are at
increased risk for osteoporosis should have bone
density determined by dual emission X-ray
absorptiometry (DXA). (Expert opinion)
Patients should consume an age- and gender-
appropriate amount of dietary calcium and should be
25-hydroxyvitamin D replete. (Clinical Principle)
Pharmacologic therapy that is directed at reducing
recurrent stone formation may also help stabilize bone
mineral density. Thiazide diuretics may increase bone
density. Alkali decreases bone resorption, especially in
patients eating a high animal protein diet, and improves
bone mass. (Expert Opinion)
Experts surmise that patientswith hypercalciuria often excrete
more calcium than they absorb, indicating a net loss of total
body calcium. The source of this additional urine calcium is
thought to originate from the skeleton. Hypercalciuric stone
formers exhibit decreased bone mineral density (BMD) and
the decrease is correlated with an increase in urine calcium
excretion [13]. The decreased BMD also correlates with an
increase inmarkers of bone turnover, aswell as increased rates
of fractures [14]. Patientswith hypercalciuria, especially those
who are at increased risk for osteoporosis, should have bone
density determined byDXA. There are few controlled studies
in hypercalciuric stone formers with low bone mass [15, 16];
however, there is awealth of data in patientswith osteoporosis
to guide therapy. Patients should consume an age- and gender-
appropriate amount of dietary calcium and should be 25-hy-
droxyvitamin D replete. Pharmacologic therapy that is
directed at reducing recurrent stone formation may also help
stabilize bone density. Thiazide diuretics lower urinary cal-
cium and may increase bone density [17]. Alkali decreases
bone resorption, especially in patients eating a high animal
protein diet, and may improve bone mass as well [18, 19].
Future research directions
• Studies to evaluate which stone formers are at most risk
of bone disease.
• Studies to evaluate which treatment(s) for recurrent
stones most favorably increase bone mass.
• Studies to evaluate which treatment(s) for osteoporosis
in stone formers most favorably increase bone mass.
Question #5
Idiopathic calcium stone: how do we define it?
A calcium stone former is considered to be idiopathic
only after exclusion of the conditions listed in Table I.
(Expert opinion)
Stone analysis of calcium stones allows one to refer
more focused lists of conditions to be ruled out to
secure the diagnosis of idiopathic stones (Table II).
(Expert opinion)
To most, ‘idiopathic calcium nephrolithiasis’ means stones
known or suspected to be made of calcium oxalate and/or
hydroxyapatite without a systemic cause. Whether or not
hypercalciuria is part of the definition is controversial. The
relevance of this question is two-fold. First, diagnosing a
stone patient as idiopathic means that a definitive treatment
of a specific etiology, if available, cannot be offered to
him; on the contrary, patients with idiopathic nephrolithi-
asis will be amenable only to a ‘generic’ pathophysiolog-
ical treatment addressing life style, nutritional, and urinary
risk factors. Second, how ‘idiopathic stones’ are defined is
relevant to clinical research. In fact, studies may not be
comparable if the definition of this prevalent condition
differs between studies.
Idiopathic stone disease is a diagnosis of exclusion but
individual practitioners’ lists of known causes to be ruled out
are not the same. Table 1 lists the criteria specifically indi-
cated in articles by some of the Faculty members [20–29].
Note that few articles in the list address the calcium stone
formerwith ‘idiopathic hypercalciuria’ [20–25]. Themajority
address generic ‘idiopathic calcium stones’where the calcium
nature of the stone has been ascertained by stone analysis or
implied by radio-opacity. On the contrary, the precise stone
718 J Nephrol (2016) 29:715–734
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composition is not generally a part of the definition of the
phenotype. However, according to the Coe and Lingeman
[21], idiopathic calcium stone formers should be restricted
only to those forming predominant calcium oxalate (CaOx)
stones (with only amarginal amount of hydroxyapatite),while
hydroxyapatite and brushite stone formers are distinct. The
Faculty has agreed that hydroxyapatite stone formers andfirst-
time stone formers with some brushite in the stone should be
investigated for systemic causes as well.
The list could be different and more focused if the precise
stone composition is known, but if this is not available the
extended list of 20 items (see Table 1) should be used. Note
that this list and the following to be applied in specific con-
ditions (Tables 2, 3) are mere opinion-based guidelines.
In reference to idiopathic CaOx stone disease, it is worth
noting that this name represents a heterogeneous group of
diseases, because a given patient may have ‘idiopathic
hypercalciuria’, ‘idiopathic hypocitraturia’ or ‘idiopathic
hyperoxaluria’, or none of these urinary risk factors.
The Faculty considered that it is reasonable to exclude
the conditions listed in Table II in a stone practice. Since it
is not possible or advisable to perform systematic genetic
studies due to the rarity of these conditions, they should be
ruled out only in those cases where there is clinical sus-
picion [30].
In reference to hydroxyapatite stones, hydroxyapatite is
a frequent constituent of calcium stones. Its representation
in a stone in a non-marginal quantity could suggest sec-
ondary forms of nephrolithiasis. The following conditions
should be ruled out before concluding that a hydroxyapatite
stone former is idiopathic: primary hyperparathyroidism,
renal phosphate wasting conditions, medullary sponge
kidney (MSK), complete and incomplete distal renal
tubular acidosis (RTA) (see below, questions #6 and #7),
abuse of absorbable antacids (calcium carbonate, the
‘modern’ form of milk alkali syndrome) and drugs inducing
proximal RTA (carbonic anhydrase inhibitors).
In reference to brushite stones, their clinical phenotype has
probably changed in recent decades. In case series recently
described, the profile of the brushite stone former is one of a
recurrent stone patient who had multiple previous extracor-
poreal shock wave lithotripsies (ESWL), and who may have
converted from another stone composition such as calcium
oxalate [31, 32]. Hypercalciuria is almost invariably present,
but complete distal RTA and primary hyperparathyroidism
Table 1 Calcium nephrolithiasis: conditions to be ruled out in the
idiopathic form
1. Hyperparathyroidism
2. Hyperthyroidism
3. Sarcoidosis
4. Vitamin D excess
5. Calcium supplements
6. Prolonged immobilization
7. Clinical evidence of bone disease
8. Malignant neoplasms
9. dRTA
10. MSK
11. Primary hyperoxaluria
12. Enteric hyperoxaluria
13. Bowel disease
14. Chronic pancreatitis
15. Vitamin C supplements
16. Chronic diarrhea
17. Lithogenic drugs
18. Urinary infection
19. Gouty diathesis
20. Cystinuria
This list is derived from [20–29]
dRTA distal renal tubular acidosis, MSK medullary sponge kidney
Table 2 Conditions to be excluded in idiopathic CaOx nephrolithiasis with hypercalciuria, hypocitraturia and hyperoxaluria
Conditions Hypercalciuria Hypocitraturia Hyperoxaluria
Primary hyperparathyroidism •
Prolonged immobilization • •
Incomplete dRTA • •
Drugs and vitamin excess • (vit. D) • (orlistat, vit.
C)
Chronic diarrhea •
Chronic pancreatitis, Crohn’s disease, gastric bypass procedures, or small bowel
resections
• •
Nephrocalcinosis • • •
Genetic conditions associated with stones (including primary hyperoxaluria) • • •
MSK • •
Abbreviations, see Table 1
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are not the cause [32]. The finding of obstructive lesions of the
urinary tract, either congenital or acquired, is particularly
notable in these stone patients [33]. The clinical phenotype is
probably different in first-time stone formers with a brushite
composition. Actually, in the older case series described by
Pak et al.[34] distal RTA was frequently observed in brushite
stone formers. Series suggest that idiopathic recurrent CaOx
stone formersmay switch to hydroxyapatite or brushite stones
over time [35]. This is hypothesized to be the consequence of
distal nephron damage induced by ESWL or previous
obstructive episodes, or of preventive treatment with alkaline
citrate [33–36]. In these hydroxyapatite or brushite patients,
no investigation for systemic condition is warranted. On the
contrary, in those patients who have passed brushite or apatite
stones for the first time, systemic causes should be looked for.
The Faculty notes that the definitions used in this section
are based on 24-h urine collection, although circadian varia-
tions in urine composition could be of great interest and value
in the pathogenesis of idiopathic calcium stone disease.
Future research directions
• Studies on the pathogenesis of hypercalciuria
• Studies on the pathogenesis of brushite stones
• Studies on the relationship between ESWL and brushite
stones
• Studies on circadian variation in urine composition
• Discovery of urinary markers of idiopathic calcium
nephrolithiasis and metabolic activity
Questions #6 and #7
Should stone patients with an incomplete distal
renal tubular acidosis be considered separately
from idiopathic calcium stone formers?
Should incomplete distal RTA be searched for in all
recurrent calcium stone formers?
Given the relatively high prevalence, the possibly
associated conditions, as well as the therapeutic
consequences, incomplete distal RTA should be
distinguished from idiopathic calcium nephrolithiasis.
(Expert Opinion)
Incomplete distal RTA should be searched for in
recurrent calcium stone formers with hypocitraturia
and less acidic urinary pH (fasting pH > 5.8) or
unexplained recurrent hydroxyapatite nephrolithiasis or
nephrocalcinosis. (Expert Opinion)
In the absence of rigorous comparative studies, the
classical short NH4Cl loading test (0.1g NH4Cl/Kg
body weight) with a cut off urinary pH of 5.3 should be
used to diagnose incomplete distal RTA. (Expert
Opinion)
The incomplete distal RTA is a condition where urinary
acidification is defective but, at odds with the complete
form, there is no systemic acidosis. Most incomplete distal
RTA cases are not diagnosed in common practice because
they are not even suspected or because of the complexity of
the diagnosis that requires the classical short NH4Cl
loading test. Incomplete distal RTA can be an acquired
condition (e.g. nephrocalcinosis, MSK, Sjo¨gren’s syn-
drome, obstruction, repeated ESWL), but it is conceivable
that incomplete distal RTA is in part due to allelic variants
of genes recognized to cause the overt form. Indeed, in a
family carrying an autosomal-recessive V-ATPase B1
subunit mutation, some heterozygous members were also
affected by recurrent CN [37].
Different test types and durations, and varying cut offs
for urinary pH for the definition of incomplete distal RTA
have been proposed. However, due to lack of rigorous
comparative studies, the validity of the different provoca-
tive test protocols in patients with (and without) recurrent
CN is currently unknown. With this limitation, incomplete
distal RTA prevalence seems to be present in between 2
and 21 % of the general calcium stone forming population
[38, 39]. Thus, incomplete distal RTA is a relatively fre-
quent condition in recurrent CN. As the stone composition
changes from CaOx to mixed CaOx-hydroxyapatite to pure
hydroxyapatite, the prevalence of incomplete distal RTA
increases from 5 to 40 % [40]. Thus, incomplete distal
RTA should be suspected in unexplained recurrent
nephrolithiasis when stones are composed mostly or
exclusively of hydroxyapatite; it should also be considered
in recurrent calcium stone formers (either CaOx or
hydroxyapatite) with hypocitraturia and less acidic urinary
pH and in patients with nephrocalcinosis. Although no
published data on 24-h urinary pH or fasting urinary pH in
patients with incomplete distal RTA is available, the Fac-
ulty has agreed that in fasting urine a pH[ 5.8 should
suggest the possible existence of an incomplete distal RTA.
There are no RCTs for the prevention of stones in
patients with incomplete distal RTA. In small studies,
treatment with alkali citrate in adults with incomplete distal
RTA decreased hypercalciuria, increased citraturia and
reduced stone recurrence [41, 42].
Future research directions
• Clinical and basic studies in the area of incomplete
distal RTA and in CN associated with incomplete distal
RTA.
• Studies in which 24-h or fasting urinary pH should be
used as a guide to indicate which stone formers should
be tested for incomplete distal RTA.
• Studies on easier test protocols for diagnosing incom-
plete distal RTA.
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Question #8
How should hyperuricosuric calcium urolithiasis
(HUCU) be diagnosed and treated?
The diagnosis of HUCU is considered in a patient with
mixed calcium oxalate and uric acid stones
characterized by idiopathic hyperuricosuria, either in
isolation or in combination with other risk factors for
calcium stones (hypercalciuria, hypocitraturia,
hyperoxalauria). (Expert Opinion)
In HUCU patients, allopurinol decreases stone events
(Grade B - Standard).
The coexistence of CaOx and uric acid in urolithiasis has
been noted repeatedly since the 1890s; Prien and Prien
observed that gouty patients passed stones which contained
or were composed of calcium oxalate; the first proposal
that HUCU represents a novel syndrome was offered by
Coe and Raisen in 1973 [43–45].
Since urine calcium and urine uric acid are correlated it
should not be surprising that there exists a group of patients
who have ‘high’ levels of both. Actually, epidemiologic
studies of a large population of uncharacterized stone-
formers failed to identify an independent association
between urinary uric acid excretion rate and risk of all
kidney stones [46]. On the contrary, earlier studies over-
looked the fact that calciuria and uricosuria are not inde-
pendently associated.
Indication of HUCU as a distinct entity mainly derives
from the ‘disputed’ pathophysiological links between uric
acid and CaOx crystallization [47–50]. Actually, several
models have been proposed that are not mutually exclusive
and can easily coexist. In fact, they can act in concert to cause
CaOx crystallization. The models include the salting out of
CaOx by urate in solution, the sequestration of various inhi-
bitors of CaOx crystallization by colloidal uric acid, and
heterogeneous nucleation or epitaxy of CaOx by uric acid/
urate crystals [50–55].Results from trialswith allopurinol also
support the idea of HUCU as a distinct entity; in these studies
the risk of calcium stones using hard clinical outcomes was
lowered [44, 56–59]. However, it remains to be demonstrated
that the favorable effect goes via a urinary urate lowering
effect. In view of the inconsistency of the definition of HUCU
in older studies, the Faculty suggests a stricter definition of
HUCU, i.e. mixed CaOx and urate stones in the presence of
hyperuricosuria with or without other risk factors for calcium
stones. This definition of HUCU permits inclusion of risk
factors such as hypercalciuria, hypocitraturia, and hyperox-
aluria but with hyperuricosuria acting as a major driver of
lithogenicity. Hyperuricosuria in these patients is idiopathic
andother diagnoses leading tohyperuricosuria shouldbe ruled
out (Table III). The Faculty notes that most of the clinical
evidence and therapeutic trials did not address HUCU as here
defined, particularly in reference to stone composition. Thus,
there is need to revisit this condition in view of the proposed
definition.
Future research directions
• Studies on the exact physicochemical basis and on the
relative contributions of each model.
• Development of the in silico way (akin to EQUIL or
JESS) of quantitatively predicting the risk of calcium
stones conferred by urine uric acid/urate.
• Studies on dose–effect of uricosuria on calcium stone
risk.
• Studies on the degree of lowering uricosuria that should
be targeted.
• Studies on the interaction of hyperuricosuria with other
urinary stone risks.
• Studies on whether the threshold to treat and the
therapeutic target differ depending on the presence and
degree of hypercalciuria, hypocitraturia, and
hyperoxaluria.
• Studies on the mechanism of the allopurinol stone-
preventive effect.
• Therapeutic trial on HUCU as here defined.
Question #9
Detection of systemic causes of nephrolithiasis - what
is the best evaluation?
All stones should be analyzed for mineral composition.
This alone will detect 3 important systemic causes of
stone disease: cystinuria (cystine stones), adenine
phosphoribosyltransferase (APRT) deficiency
(dihydroxyadenine stones), and urease driven
infection stones (struvite stones). Furthermore, it will
detect stones induced by drugs. (Clinical Principle)
A standard urinalysis will provide an important screen
for several systemic causes of stones: urinary tract
infection (pyuria); Dent disease (proteinuria);
cystinuria, and struvite stones (characteristic
crystalluria). (Clinical Principle)
Table 3 Conditions to be excluded in hyperuricosuric calcium
urolithiasis
Overproduction Renal leak
Gout/metabolic syndrome Uricosuric agents
Dietary purine overload Rare transporter diseases
Catabolic states
Rare monogenic diseases
of purine metabolism
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A careful history can detect risk factors or clues for
specific causes of stones: bowel resection or bariatric
surgery (enteric hyperoxaluria [small bowel resection]
or uric acid stones [ileostomy]); drug stones; and
prolonged immobilization (hypercalciuria). (Clinical
Principle)
Serum for creatinine, calcium, phosphorus, K, Mg,
HCO3, Cl, and uric acid will detect important factors
that influence stone risk and/or treatment choices.
(Clinical Principle)
A 24-h urine test for creatinine, pH, calcium, oxalate,
citrate, uric acid, and qualitative cystine will detect
major systemic causes of stone disease. If the panel is
normal, a systemic cause is unlikely. If abnormal, a
directed workup is indicated. (Clinical Principle)
All patients should have the composition of their urinary
stones analyzed at least once. This is a cheap and valuable
test that quickly identifies specific potential causes of stone
disease. Importantly, a stone analysis alone can detect three
important systemic causes of stone disease: cystine stones
are diagnostic of cystinuria, dihydroxyadenine stones of
APRT deficiency, and struvite stones of infection from a
urease-positive organism. Other rare causes like drugs will
also become apparent on a stone analysis.
A standard urinalysis with microscopy is an important
screen for several systemic causes of stones. Pyuria sug-
gests possible urinary tract infection. A high pH ([7.5)
makes infection with a urease-positive organism possible,
while a secondarily infected stone can be seen across the
entire pH range. Proteinuria, especially in a male patient,
makes it important to rule out Dent disease by confirming
the nature of the proteinuria (i.e. screen for low molecular
weight proteins like retinol binding protein, alpha-1
microglobulin, or beta-2 microglobulin). Crystals of
cystine, dihydroxyadenine, and struvite are also charac-
teristic in appearance, and these diagnoses can be con-
firmed with other tests.
A careful history is an essential part of a urinary stone
evaluation. A history of any form of gastrointestinal dis-
ease suggests possible specific risk factors. Diseases that
affect the small intestine or pancreas, including Crohn’s
disease, gastric bypass procedures, or chronic pancreatitis,
often lead to fat malabsorption and enteric hyperoxaluria.
Gastrointestinal diseases that are associated with chronic
diarrhea also cause excessive loss of bicarbonate in the
stool and hence an appropriately low urinary pH, which
raises the risk of uric acid stones. An intact colon is nec-
essary for enteric hyperoxaluria. Hence, conditions with
large gastrointestinal losses of fluid without a colon, e.g.
the presence of an ileostomy, are typically associated with
uric acid and not CaOx stones. Finally, certain fairly rare
disorders such as sarcoidosis, or prolonged immobilization
are associated with rapid loss of bone calcium and
hypercalciuria.
A serum test for creatinine, calcium, phosphorus, K, Mg,
HCO3, Cl, uric acid can effectively screen for important
risk factors that influence stone risk factors and/or treat-
ment choices. Hypercalcemia is an important sign of
hyperparathyroidism, as well as rare conditions such as
CYP24A1 mutations or sarcoidosis. A low serum phos-
phorus is also consistent with hyperparathyroidism. A low
potassium can contribute to hypocitraturia and/or suggest
RTA, while a low serum bicarbonate suggests chronic
gastrointestinal losses or RTA. An elevated serum crea-
tinine suggests CKD, which can influence the choice of
treatments like potassium citrate.
Systemic causes of urinary stone disease are associated
with predictable urinary abnormalities. Hence, a 24-h urine
for creatinine, pH, calcium, oxalate, citrate, uric acid, and
qualitative cystine is useful to detect major causes of stone
disease. For example, a low urine pH and low urine citrate
suggests gastrointestinal base losses, and a high urine pH
and low citrate indicates possible RTA. Hyperoxaluria
makes it important to consider enteric or primary hyper-
oxaluria, and hypercalciuria makes it essential to consider a
systemic disease of calcium metabolism. Conversely, if all
elements of the 24-h urine are normal, a systemic cause of
stone disease is less likely.
Future research directions
• Studies on the performance of different diagnostic
algorithms in identifying secondary forms of
nephrolithiasis.
Question #10
Is the measurement in urine of some index of
lithogenic risk clinically useful?
The overall lithogenic risk cannot be estimated in
urine. The best approximation is the determination of
the upper limit of metastability (ULM). However,
ULM measurement is only suitable for research
purposes. (Expert Opinion)
Determination of the relative supersaturation (RS)
could be useful to improve patient’s compliance to
preventive treatment of calcium nephrolithiasis.
(Expert Opinion)
Relative supersaturation (RS) of urine for calcium con-
taining stone-forming species is the essential condition for
a stone to form. RS can be easily estimated with a dedi-
cated algorithm (Equil, JESS, Lithorisk). However, RS
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does not fully represent the overall lithogenic risk since it
fails to estimate the inhibitory potential of urine and of the
cells-crystal interaction in the renal tubule. There are no
available data from pharmacologic RCTs with follow-up
and treatment guided by urine supersaturation levels;
hence, it is not established whether changes in urine
supersaturation measurements predict reduced risk of
recurrent stones with drug treatment. However, experts
believe that measuring RS levels during follow-up may be
a useful tool for increasing patient compliance.
The ULM is defined as the value of RS where sponta-
neous crystallization in urine occurs. It is different from RS
because it is influenced by the inhibitory potential of urine.
However, it still does not estimate the contribution of the
cells-crystal interaction. Furthermore, ULM determination
is time-consuming and not standardized.
Future research directions
• Studies on standardization of methods for ULM
determination and application to larger numbers of
stone forming and non-stone forming subjects.
• Studies investigating whether follow-up and treatment
guided by urine RS determination decreases stone
recurrences.
Question #11
Is the observation of the urine sediment clinically
useful in calcium stone formers?
In calcium stone disease, analysis of crystalluria is of
limited clinical value in the diagnostic workup, and is
not recommended for treatment follow-up. (Grade C -
Recommendation)
A major limitation of studies of crystalluria is the lack of
standardization since urine can be examined fresh or
stored, collected after fasting or as a 24-h study, cen-
trifuged or evaporated, and quantified by coulter counter or
microscope.
Studies in patients with CN have addressed frequency,
composition, size and volume, agglomeration and attach-
ment of crystals. Using fresh voided urine, it was found that
crystalluria was more prevalent in calcium stone formers
than in controls, but the type of crystals did not differ [60].
The type of CaOx crystals (whewellite vs. weddellite) seems
to discriminate to a degree between hyperoxaluric and
hypercalciuric stone formers [61]. Volume of crystals was
higher in stone formers [62, 63]. However, crystal presence
was not modified by different treatments even though the
type of crystals changed from more calcium phosphate to
more CaOx [60]. Presence of crystals was poorly related to
degree of supersaturation [63].
Crystal agglomeration was more frequent in stone
formers but of low incidence (1.4–8 %).
Inhibition of stone agglomeration exhibited some cor-
relation with efficacy of treatment [64].
Future research directions
• Crystal aggregation (agglomeration) and crystal-cell
interaction may be of clinical use in the future. At
present, data are too scarce. For a better understanding
of the mechanism of stone formation, it may be
worthwhile to combine urine crystal analysis with
endoscopic analysis of papilla, correlating it with the
presence of plaques and plugs.
Question #12
Is measurement of crystallization inhibition in urine
of clinical value?
Measuring inhibition of crystallization and crystal
aggregation in urine is not recommended since
methods are cumbersome and the only way to
manipulate it, i.e. the administration of citrate, is
decided on the direct measurement of citraturia. (Grade
C - Recommendation)
This question is flawed by the lack of a clear demonstration
of a role of crystallization inhibitors and crystal aggrega-
tion inhibitors in CN. Furthermore, clinical value could
only be obtained if:
1. it is known which inhibitors that affect the relevant
processes differ between people who do vs. do not
form stones,
2. measuring this difference can be done in a high
throughput manner, and
3. the inhibitory action can be manipulated.
Studies on crystallization inhibition/inhibitors are
numerous. However, they often lack standardization or
were not designed to exactly mimic the environment
where stones are thought to form by the two mecha-
nisms described above. Study quality is low to mod-
erate. The majority of studies dealt with individual
urine compounds. Only a few studies include compar-
ison of a stone former group to a control group. Even
fewer studies actually compare inhibitory action of
urine between the two groups. No studies were found
that apply conditions resembling the renal interstitial
fluid.
With respect to crystal growth, the results of the
comparison between people who do or do not form
stones are not uniform and only suggest the following
expert opinion: urine contains many compounds that can
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inhibit crystal growth. In urine, macromolecules with an
affinity for calcium deliver most of the growth inhibition
capacity. However, when these compounds are lacking
in quantity or function their action is taken over by other
inhibitors that are also present in the urine. This over-
load of growth inhibitors may explain why crystal
growth inhibition does not differentiate stone formers
from controls.
With respect to crystal aggregation (or agglomeration)
fewer studies are available but the conclusion is more
uniform [65, 66]. Stone formers produce larger particles,
mainly aggregates, and their urine is less able to inhibit
crystal aggregation. Some studies show a correlation
between the severity of the disease, expressed as number of
stones formed per patient, and capacity to inhibit aggre-
gation. This capacity seems to be exerted both by an
interplay between macromolecules and small molecules
like citrate [66]. Interventions that aim to increase the urine
citrate content also increase the aggregation inhibition.
There is no standardized method to measure crystal
aggregation inhibition by whole urine in a high throughput
method.
Future research directions
• Studies on the role of crystallization inhibitors and
crystal aggregation inhibitors in stone formation in the
interstitium (Randall’s plaque precursors), and in the
interface with papillary deposits (Randall’s plaque),
and ductal plugs.
Question #13
Are surgical observations during stone treatment
potentially useful for the diagnosis and prognosis of
nephrolithiasis?
The endoscopic evaluation of papillae in stone formers
could provide valuable information in the diagnostic
workup of stone formers, and a scoring system for
papillary pathology in stone formers has potential
utility in diagnosis and prediction of prognosis of
disease. (Expert Opinion)
Recent studies that have utilized endoscopy and papil-
lary biopsy for the study of stone patients have revealed
that stone formers differ not only in the types of mineral
that they deposit in their stones (CaOx, brushite, struvite,
etc.) but also in the pathology of their renal papillae with
regard to the presence of Randall’s plaque and ductal
plugging [26, 27, 33, 67–74]. Moreover, there is at least
some correlation between the histopathologic pathologies
observed in a papillary biopsy and the visual appearance
of the same papilla before biopsy [75]. Thus, although
stone formers have classically been divided by the
minerals contained in the stones that they form [76], the
possibility exists that this classification could be
improved—or perhaps even replaced—by endoscopic
observations during minimally invasive removal of renal
stones.
The consensus of the working group was that endo-
scopic evaluation of papillae in stone formers could defi-
nitely have value, and that a scoring system for papillary
pathology in stone formers has potential utility in diagnosis
and prediction of prognosis of disease. We note that the
first publications of a papillary scoring system have
recently emerged [77–79].
Study of the utility of a papillary scoring system in
stone formers calls for correlation with prognosis of dis-
ease and prediction of recurrence of stones. There is
already some evidence for the correlation of papillary
computed tomography (CT) density (which is increased
by the presence of small stones or ductal plugs [80]) with
stone recurrence rates [81]. Endoscopic observation of
papillary pathology is more informative than CT [80], and
thus logically could be more predictive of stone recur-
rence. Similarly, evidence for the connection of stones
with CKD [82, 83] may well be informed by papillary
pathology, as the plugging of collecting ducts is a prob-
able cause of kidney injury. Finally, the working group
was convinced that evaluation of papillary pathology
endoscopically also could have the potential to indicate
the direction of metabolic diagnosis and treatment for a
given patient [84].
Future research directions
• Development of papillary scoring systems, including
validation by external observers, with subsequent study
of the utility of each scoring system in clinical practice.
• Studies of the correlation of papillary pathology with
prognosis of disease and prediction of recurrence of
stones.
Question #14
Is stone analysis and stone morphology of clinical
utility?
Stone analysis should be done with modern methods,
either infrared (IR) spectroscopy or X-ray diffraction.
Since stone composition can change in a patient over
time, stone analysis should be done regularly and in a
standardized fashion. (Clinical Principle)
More work needs to be done before stone morphology
can be added to standard stone analysis. (Expert
Opinion)
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Stone analysis is not uniformly well done around the world
- or even uniformly well done within countries [85, 86].
Thus it is not surprising that data on stone composition
have not been correlated well with patient outcomes. This
is especially true for stone analysis done by wet chemical
methods, where the errors inherent within such analyses
[85, 87] would certainly preclude any ability to identify
relationships between stone components and patient
characteristics.
But even with the use of modern spectroscopic
methods of analysing stone mineral, the existing practice
has limitations. For example, evaluation of the compo-
sition of mixed stones relies on skilful dissection of the
specimen, which may not always happen [86]. There are
also several reports that suggest that the recognition of
special stone morphologies can be pathognomonic for
certain conditions [88–90], but there is no evidence that
these morphologies are being widely recognized in
analysis practice.
Although progress is being made in the use of dual-
energy CT to identify stone composition [91], it is unlikely
that this will ever replace stone analysis, as the spatial
resolution required to assess stones of multiple components
is quite fine [92]. Thus, the working panel concluded that
work needs to be done to improve existing practices of
stone analysis. Even though a detailed model for proper
stone analysis exists, this model needs to be emulated by
other sites. There is much need for education, as methods
across countries are not consistent, and there are few
practices for testing that are widespread [93]. In addition,
the nomenclature for stone components needs to be stan-
dardized [86].
The working panel was convinced that stone analysis
should be done, and because stone composition can change
in a patient over time [94, 95], it should be done regularly
and in a standardized fashion. In addition, although rare
stones are indeed rare, stone analysis is inexpensive and
delay in recognizing a rare stone in a patient can lead to
loss of kidney function that would have been preventable if
the rare stone had been recognized upon first presentation
[96]. Although the panel was convinced that observation of
stone morphology has potential utility, it concluded that
more work needs to be done before this can be added to
standard stone analysis.
Future research directions
• Educational work needs to be done to improve existing
practices of stone analysis.
• Nomenclature for stone components needs to be
standardized.
• More work is needed on stone morphology to imple-
ment it in stone analysis.
Questions #15, #16 and #17
Who is the recurrent calcium stone former? How
should metabolic activity be determined? How should
calcium stone formers be evaluated?
A single calcium stone former is a patient who seeks
advice for a single, solitary kidney stone episode and
who has no other stones seen by imaging in the kidney.
A recurrent calcium stone former is a patient with
multiple kidney stones, which can occur at the same
time or be temporally spaced. Metabolically active
stone disease is identified by new stone formation or
stone growth on serial imaging. Yet, the underlying
disorder can only be identified by performing a
comprehensive metabolic evaluation. Studies suggest
that metabolic activity will persist, but can be
controlled with dietary or medical management.
(Expert opinion)
The recurrent stone former, and the single stone
former, whenever considered at high clinical risk for
recurrence (younger age, family history of
nephrolithiasis, etc.), should be evaluated
comprehensively, including preferably two 24-h urine
studies on a random diet at least 3-4 weeks after stone
passage or treatment. (Grade B - Standard)
The distinction between single and recurrent stone formation
is usually based on clinical evidence of either isolated or
multiple episodes of stones, but this definition is not precise.
Imaging studies complement the definition of stone recur-
rence. Stone recurrence and/or growth are indications of
‘metabolic activity’. The concept of metabolic activity of
stone disease means the existence of an ongoing crystalliza-
tion-driving process that most likely will lead to new stones or
to the growth of already existing stones. It is the concept of
metabolic activity that should ideally drive the clinician’s
decision on how to treat the stone patient. Single and recurrent
stone formers share many similarities in their metabolic pro-
files [97, 98]. There are no markers that may distinguish
between single and recurrent stone formers andmetabolically
active vs. metabolically inactive stone formers. A nomogram
(ROKS) for the prediction of a second (recurrent) symp-
tomatic stone episode has been recently proposed [99].
However, only symptomatic stones were considered and the
10 years recurrence rate was only 30 % on the whole, and no
more than 56 % in the subgroupof patients at highest risk. The
evaluation of the stone patient should also address the
patient’s risk factors for recurrent stone formation or other
morbidities and indications. These risk factors and conditions
include, but are not limited to, family history of stone for-
mation; pediatric age; solitary kidney; patients with concur-
rent medical conditions; nephrocalcinosis, CKD or skeletal
diseases; history of bowel disease or bowel surgery; patient’s
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job (i.e. pilots, frequent business travelers); difficult to treat
stones (e.g. urinary tract abnormalities/reconstruction); and
immuno-compromised conditions.
Future research directions
• Studies on markers that predict stone recurrence.
• Studies on metabolic markers that distinguish metabol-
ically active vs. metabolically inactive stone formers.
Questions #18 and #19
Should we follow patients with non-active idiopathic
calcium nephrolithiasis and how?
How do we follow patients with calcium
nephrolithiasis under preventive treatment?
Single stone formers without clinical risk for
recurrence should be offered an initial simplified
metabolic evaluation and a clinical follow-up.
According to the level of metabolic activity presented
during this follow-up or to changes from the initial
presentation the clinician should perform a more
thorough and frequent follow-up. (Expert opinion)
A follow-up 24-h urine collection should be repeated
after 3-6 months from the start of selective medical
therapy, to assess response to dietary and/or medical
therapy or for adverse effects. Metabolic follow-up
thereafter can be performed yearly to assess the
effectiveness and adherence to medical therapy. More
frequent follow-up is recommended based on stone
composition, such as in brushite stone formers; patients
with recurrent or multiple stones; those with a family
history of stone formation; patients with difficult to
treat stones; children with calcium stones; stone
formation in a solitary kidney; patients with
concurrent medical conditions; individuals with CKD
or nephrocalcinosis or skeletal diseases; and those with
a history of bowel disease or bowel surgery. Other
relative indications for a more frequent follow-up
include: those patients whose job requires they be
without stones (i.e. pilots, frequent business travelers);
patients with difficult to treat stones (i.e. urinary tract
abnormalities/reconstruction); and individuals who are
immuno-compromised. (Expert Opinion).
Periodic imaging performed annually allows for an
assessment of clinical activity, defined as new stone
formation or stone growth, though the timing and type
of imaging can be tailored based on stone composition,
activity and location (renal or ureteral), as well as
clinical signs and symptoms. DXA should be repeated
over time, whenever osteopenia or osteoporosis is
detected on the metabolic evaluation (Expert Opinion).
Follow-up is the mainstay of conservative and active
management of CN, to prevent both stone growth and
new stone formation. The greatest challenge in fol-
lowing stone formers is their low adherence to con-
servative or selective medical recommendations,
particularly dietary advice. The purpose of follow-up is
to assess the efficacy of treatment, to encourage patient
compliance and ultimately reduce the risk of stone
recurrence. Through close monitoring, the clinician is
able to assess treatment adherence to or effectiveness
of recommendations, allowing adjustment of pharma-
cological treatment dosing and the determination of
both short- and long-term adverse effects of directed
medical therapy. However, continued management of
patients with stone disease varies widely between
practitioners, since no studies have assessed an optimal
schedule as the primary outcome. Despite the lack of
evidence-based principles, systematic reviews of the
literature and recently published guidelines help to
establish which laboratory or imaging studies should be
performed, their frequency and duration, and also to
define the target population: single and/or recurrent
stone formers [1, 2].
Future research directions
• Studies on the fate of asymptomatic stone formers.
Should patients with renal stone(s) incidentally found
in imaging studies undergo a metabolic evaluation and/
or follow-up?
• New stone formation and stone growth are not
always distinguishable depending on different imag-
ing modalities. Future observational studies or RCTs
should employ sensitive and, more importantly,
standardized detection methods. They should define
an absolute stone size or growth rate threshold(s) in
order to ascertain the presence of baseline residual
stones, and then to establish measurement of stone
growth. The use of standard modalities and appro-
priate testing frequencies, to ascertain incident
radiographic stones should be defined. Patients with
asymptomatic stone growth, radiographic stone
recurrence and/or asymptomatic stone passage
should be followed untreated for several years for
symptomatic stone recurrence to help determine
whether and under what circumstances these mea-
sures can serve as appropriate surrogates for symp-
tomatic stone recurrence. RCTs should separately
report the outcomes of symptomatic and radio-
graphic stones, describe the laboratory and radio-
graphic testing that participants undergo, including
their cumulative radiation exposure.
726 J Nephrol (2016) 29:715–734
123
Question #20
Is any special beverage likely to matter apart from
being a way to provide water?
Patients with calcium nephrolithiasis should maintain a
fluid intake sufficient to achieve a urine volume of at
least 2.0 to 2.5 l/d. (Grade A - Standard)
Reduced sugar-sweetened soft drink intake lowers
recurrence risk in patients with high baseline
consumption. (Grade B - Standard)
The intake of orange juice with no added sugar might
confer protection toward calcium nephrolithiasis.
(Grade C - Recommendation)
A low urine volume is one of the most important risk factors
for urinary stone formation. OneRCT showed that idiopathic
CaOx stone formers who increased fluid intake to maintain a
urine volume of greater than 2 l/day had a significantly lower
recurrence rate during the 5-year follow-up period than the
control group (12.1 vs. 27.0 %, p = 0.008) [100]. Another
trial in CaOx stone formers who became stone free after
shock wave lithotripsy found a decrease in stone recurrence
in patients with increased fluid intake to achieve more than
2.5 l of urine per day compared with no treatment for
2–3 years (8.3 vs. 55.6 %, p\ 0.05) [101].
By contrast, there is unfortunately no hard data on the
importance of water composition. In both healthy subjects
and patients with recurrent CaOx urolithiasis, an elevated
intake of mineral water with a very high bicarbonate and
magnesium content (28 and 44 mEq/l, respectively) was
shown to produce higher urinary citrate and magnesium
excretion compared to an equal amount of control water and
to significantly alkalinize urine [102, 103]: nevertheless, the
observed decrease in urinary super-saturation for CaOx was
comparable to that obtained with the control water and
mostly due to the increase in urine volume, whereas super-
saturation for calcium phosphate was significantly increased
due to the significant rise in urinary pH.
Most controlled clinical trials testing the effect of water
with a high calcium content in calcium stone patients
observed increases in urinary calcium excretion paralleled
by a decrease in urinary oxalate excretion, presumably due
to increased oxalate complexation by calcium in the gut
and subsequent reduced intestinal absorption of free oxa-
late. However, the long-term effect on stone recurrence rate
is unknown [104].
A prospective observational study on three large cohorts
of individuals without a history of nephrolithiasis found
that the risk of incident kidney stones was directly asso-
ciated with consumption of sugar-sweetened beverages and
inverse associations with the intake of orange juice but also
with the consumption of both caffeinated and decaffeinated
coffee, tea, beer and wine [105]. In a large RCT in stone-
forming men with a high baseline sugar-sweetened bever-
age consumption, abstinence from soft drink intake sig-
nificantly reduced the risk of recurrence at 3 years
compared to the control group (33.7 vs. 40.6 %,
p = 0.023) [106].
Overall, there is sound evidence against the consump-
tion of sugar-sweetened beverages and circumstantial evi-
dence in favour of orange juice intake with no added sugar
for prevention of CN.
Future research directions
• Controlled trials of the effects of different types of
beverages, including bicarbonate-rich mineral water
and water with different calcium content, on the rate of
stone recurrence in patients with CN are warranted.
Question #21
Do diet treatments prevent calcium oxalate stones?
Any recommendation for prevention of calcium
nephrolithiasis should be seen in the framework of a
well-balanced healthy diet that is also effective for the
prevention of major chronic degenerative disorders.
(Expert Opinion)
Dietary intervention should be based on the assessment
of the patient’s habitual diet and the identification of
specific metabolic risk factors, if any, for calcium
oxalate nephrolithiasis. (Expert Opinion)
Calcium-oxalate stone formers with hypercalciuria
should maintain a dietary calcium intake not lower
than 1000 mg/day, a sodium intake not higher than 2.4
g/day (or 6 g of salt) and a moderate intake of non-
dairy animal protein (i.e. 0.8 g/kg body weight or less
(Grade A - Standard).
Calcium-oxalate stone formers with high urinary
oxalate excretion benefit from a normal dietary
calcium intake and reasonable limitation of selected
oxalate-rich foods. (Grade C - Recommendation)
Calcium-oxalate stone formers with low urinary citrate
excretion should increase their intake of fruits and
vegetables and limit non-dairy animal protein. (Grade
C - Recommendation)
Vitamin C supplementation increases the risk of
calcium nephrolithiasis (Grade B - Standard).
Combined Vitamin D and calcium supplementation
may increase the risk of calcium nephrolithiasis; thus,
when needed, it should be prescribed with periodic
monitoring of urinary calcium excretion. (Grade C -
Recommendation)
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An observational study supports the idea that the Dietary
Approaches to Stop Hypertension (DASH) diet, an exam-
ple of dietary model designed for the prevention of car-
diovascular diseases, may be effective also in primary
prevention of CN [107]. The Mediterranean diet [108] and
the lacto-ovo vegetarian models [109] are other examples
of healthy well-balanced diets with many features poten-
tially effective for the prevention of CN.
It has been recognized that dietary recommendations
tailored to the specific patient condition are more likely to
be effective than non-specific dietary advice in preventing
recurrences [110].
An RCT showed that an interventional diet consisting of
normal calcium, low sodium and low animal protein con-
tent, associated with high fluid intake, effectively reduced
the rate of stone recurrence as compared to high fluid
intake associated with a low calcium diet [20]. In addition,
high quality prospective studies showed that a normal
dietary calcium intake (1000-1200 mg/day) for most adult
individuals is associated with a reduced risk of stone for-
mation compared to lower intakes [111–116]. Both clinical
[117] and epidemiological studies [118] suggest to reduce
sodium intake since the higher the salt intake, the greater
the calcium excretion [119].
Large high quality cohort studies in the general popula-
tion have demonstrated an inverse relationship between
dietary calcium intake and urinary oxalate excretion
[111, 120, 121]. When the recommended intake of calcium
was achieved, even a relatively high dietary oxalate intake
was not associated with higher CaOx stone risk [120].
Although these studies did not target recurrent CNpatients, it
is conceivable that patients with hyperoxaluria and a history
of CaOx stones would also benefit from a relatively high
calcium intake (1000-1200 mg/day) on the same grounds.
As the urinary oxalate excretion is significantly related to the
amount of oxalate in the diet120, a limited consumption of
selected oxalate-rich foods is advisable in these patients. On
the other hand, extreme restriction of dietary oxalate is
impractical and possibly dangerous as it would result in
lower intakes of fruits, vegetables and whole grains which
are known to provide other major health benefits [120, 121].
A fruit and vegetable rich diet significantly increases the
urinary citrate and phytate excretion [122] and was found
to be protective against CN in a number of good quality
observational prospective studies [20, 107, 123]. By con-
trast, a high dietary acid load reduces urinary citrate [124]
and a good quality observational prospective study has
shown that fish and poultry proteins are associated with
increased risk of first-stone formation as opposed to veg-
etable and dairy proteins [125]. Thus, patients with
hypocitraturia should be instructed to reduce non-dairy
animal protein intake.
The results of good quality population-based prospec-
tive studies are consistent with a higher risk of CN in males
taking vitamin C supplements [126, 127]. There is also
circumstantial evidence in post-menopausal women that
combined intake of vitamin D and calcium supplements
increases the rate of incident CN [128].
Future research directions
• RCTs on the value of complex dietary patterns, such as
the Mediterranean diet, in primary and secondary
prevention of nephrolithiasis are warranted.
Questions #22, #23 and #24
When to use citrate?
When to use thiazides?
When to use oral phosphate?
Potassium citrate is indicated in recurrent CaOx and
calcium phosphate stone formers with: 1) low or
relatively low urinary citrate excretion; 2) complete or
incomplete distal RTA, chronic diarrheal states, drug-
induced or diet-induced hypocitraturia, and 3)
osteopenia/osteoporosis. (Grade B - Standard)
Thiazides are appropriate for both CaOx and calcium
phosphate stones in hypercalciuric stone formers, and
even in normocalciuric patients when dietary measures
and increased fluid intake have not prevented stone
recurrence. (Expert Opinion)
There is no evidence supporting the use of any
phosphate supplement in the treatment of idiopathic
calcium nephrolithiasis. (Expert Opinion)
The relative merits and drawbacks of citrate and thiazides
in stone prevention are well known but they have not been
compared head-to-head in any trial. Discussion of the risks
and benefits of both treatments should ensue with patients,
whose values should be taken into consideration.
Citrate inhibits crystallization processes in calcium
stone formers. Potassium citrate is therefore indicated for
the following clinical situations: (1) recurrent CaOx and
calcium phosphate stones with low or relatively low uri-
nary citrate excretion; (2) patients with complete or
incomplete distal RTA, chronic diarrheal states, drug-in-
duced or diet-induced hypocitraturia [41, 42, 129–131],
and known osteopenia or osteoporosis. In case of intoler-
ance to citrate, potassium bicarbonate can be used instead.
Sodium citrate should be avoided because sodium pro-
motes calcium excretion and is less effective at promoting
citrate excretion than potassium salts [132].
Thiazide diuretics should be offered to patients with
high or relatively high urine calcium and recurrent calcium
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stones [133–138], although the precise mechanism of thi-
azide action has not been elucidated. The AUA guidelines
[1] also suggest that thiazides would be useful in patients
without relatively high urine calcium excretion as lowering
urine calcium excretion may be effective regardless of the
absolute rate of calcium excretion. Some studies showing
efficacy of thiazides did not require hypercalciuria at
baseline. Thiazides would be appropriate when dietary
measures and increased fluid intake have not prevented
stone recurrence. Under these circumstances, thiazides are
considered appropriate for both CaOx and calcium phos-
phate stones. Appropriate doses and regimens include
hydrochlorothiazide 25 mg twice a day, chlorthalidone
25 mg once a day or indapamide 2.5 mg once a day.
Thiazides should always be administered with potassium to
avoid increased cardiovascular risk and minimize glucose
intolerance [139, 140]. Potassium citrate supplementation
may be preferred to potassium chloride to maintain urinary
citrate excretion, improve bone mineral density and reduce
urinary calcium excretion. Alternatively, potassium loss
can be counteracted by amiloride 5 mg or spironolactone
25 or 50 mg. Triamterene should be avoided.
Both citrate and thiazides appear to increase bone
mineral density, a frequent correlate of hypercalciuria and
calcium stones. Possibly these effects are synergistic
though the combination has not been specifically tested.
Thiazides may be considered the blood pressure lowering
drugs of choice in patients with kidney stones as they have
consistently been shown to be the preferred agents for the
treatment of essential hypertension, systolic hypertension,
and hypertension in the elderly because of their consistent
effect to lower cardiovascular morbidity and mortality.
Treatment with oral phosphate results in reduction in
urinary calcium excretion largely due to inhibition of cal-
citriol synthesis [141]. One main concern with oral phos-
phate administration has been the possibility of metastatic
soft tissue calcifications resulting in renal functional
impairment. One long-term, blinded controlled study in a
small number of absorptive hypercalciuric kidney stone-
forming subjects using sustained released potassium
phosphate showed the safety of this preparation [142].
However, the efficacy was not tested in a multicenter trial
using incident kidney stone episode as an outcome.
Future research directions
• RCTs on the pharmacological prevention with thiazides
of recurrent calcium stone disease with different
biochemical phenotypes (normo- and hypercalciuric,
etc.).
• Since the pharmacological armamentarium for renal
stone prevention is quite limited there is need of studies
investigating new drugs to prevent stone recurrence.
Question #25
Is the use of citrate safe in reference to the risk of
calcium phosphate lithogenesis during calcium
oxalate stone prevention?
The use of citrate treatment in patients with calcium
oxalate stones is safe provided that the urinary citrate
increase is commensurate with the rise in urinary pH.
(Expert Opinion)
In two open trials in patients with distal RTA and MSK
prone to calcium phosphate stone formation, citrate treat-
ment significantly reduced the prevalence of kidney stones
[41, 42]. However, in one retrospective study it was shown
that those who transformed the stone composition to cal-
cium phosphate stones had a higher baseline and post
treatment urinary pH compared to non-transformers [143].
Due to the sparsity of controlled studies delineating the risk
of calcium phosphate stone formation with alkali therapy,
alternatives to alkali treatment should be tested in
prospective clinical studies. Until such a study is per-
formed, clinicians should offer citrate treatment to patients
with calcium phosphate stones in whom urinary citrate
increases commensurate with a rise of urinary pH.
Future research directions
• Due to the potential risk of calcium phosphate stone
formation with alkali treatment, alternatives to alkali
treatment should be tested in prospective clinical
studies using citric acid vs. potassium citrate or
thiazide ? potassium chloride vs. thiazide ? potas-
sium citrate in this population.
Questions #26 and #27
When should the urologist and the nephrologist
collaborate?
How should such a cooperation be implemented?
Before elective surgery:
Collaboration between urologists and nephrologists is
advocated for the assessment of the etiology of renal
stones in order to prevent sudden relapses in secondary
forms of nephrolithiasis and in patients with advanced
renal failure for the evaluation of the risk-benefit ratio
of the intervention. (Expert Opinion)
Either before or after elective surgery:
Collaboration between urologists and nephrologists is
advocated in patients with severe stone disease, or
those with a putative high risk of recurrence where a
comprehensive diagnostic workup or the expertise are
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not available in urology; furthermore, it is advocated in
patients with CKD or at risk of CKD, single kidney,
anatomical urinary tract abnormalities, and in patients
with infected stones. (Expert Opinion)
Collaboration can be enhanced on a local level by
Multidisciplinary Stone Meetings (educational and for
discussion on active clinical cases), local protocols and
guidelines, and joint stone teams. (Expert Opinion)
Nephrologists and urologists have been working side by
side for a very long time. Yet, too often, there seems to be a
rivalry, almost a competition, as can be found in many
places between physicians and surgeons. Naturally, given
the different approaches to disease, their view of the world
and even their ‘dialects’ differ [144]. This poses a barrier
between the two specialties that applies also to stone dis-
ease, which is often complex and caused by certain
underlying co-morbidities that cannot be tackled by blast-
ing the stone alone. Conveniently, though, for the urolo-
gists, developments in stone blasting technologies have
made treatment very smooth and easy, leading to a neglect
in looking for the diagnosis of underlying causes. On the
other hand, nephrologists show only a limited interest in
stone disease amongst all the other renal pathologies they
have to deal with.
We believe that in the clinical management of patients
with nephrolithiasis, the collaboration between nephrolo-
gists and urologists is crucial. A close collaboration based
on each other’s understanding is needed not only during the
acute phase of stone-related renal injury, but also during
the clinically stable phase of the disease. However, in a
global perspective this principle is not generally applicable
and it needs to be emphasized that such a shift in routine
cannot be accomplished without a change in the education
of nephrologists. In a survey of urologists performed before
the conference to obtain a better picture of their urologists’
point of view, 51 % of respondents claimed to refer stone
formers to nephrologists ‘‘occasionally’’ and, more worri-
some, 39 % said ‘‘never’’. Yet, secondary and metabolic
stone disease were the main reasons for referral to the
nephrologist.
Currently, we are not aware of any guidelines for urol-
ogists regarding nephrology referrals. A recent study shows
a poor implementation of guidelines among healthcare
providers [145], and we may assume this to be true for
urologists and nephrologists as well. Searches in literature
databases for such guidelines using an array of search
terms did not reveal any hits.
Future research directions
• As part of an integrated clinical management pathway
for nephrolithiasis patients, the nephrologist and
urologist—ideally in collaboration—will have to face
the development of shared protocols for the evaluation
of stone formers and for defining cooperation.
• The evaluation of Quality and cost/benefit ratio of the
protocols for renal stone forming patients.
• Cost/benefit analysis of instrumental investigations for
the follow-up of renal stone forming patients (economic
cost, radiological risks).
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